AICD binding to the MAST4 promoter was lower in late-onset AD brains compared to control cases (no neurologic disease) and FTD brains (Fig. 6A), which was accompanied by less MAST4 mRNA and protein abundance (Fig. 6B–D). Here, MAST4 is linked to nervous system disorder.